Verastem gets priority review for ovarian cancer therapy
PDUFA target action date is June 30, 2025
If approved, avutometinib in combination with defactinib would be the first-ever FDA-approved treatment specifically for adults with recurrent KRAS mutant LGSOC
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.